Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2

PHASE2CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

March 23, 2020

Primary Completion Date

May 7, 2020

Study Completion Date

June 7, 2020

Conditions
SARS-CoV InfectionSevere Acute Respiratory Syndrome (SARS) Pneumonia
Interventions
DRUG

Chloroquine diphosphate

150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).

Trial Locations (1)

69093-415

Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus

All Listed Sponsors
collaborator

Marcus Vinícius Guimarães de Lacerda

UNKNOWN

collaborator

Mayla Gabriela Silva Borba

UNKNOWN

collaborator

Wuelton Marcelo Monteiro

UNKNOWN

collaborator

Gisely Cardoso de Melo

UNKNOWN

collaborator

Fernando Fonseca de Almeida e Val

UNKNOWN

collaborator

Felipe Gomes Naveca

UNKNOWN

collaborator

Maria Paula Gomes Mourão

UNKNOWN

collaborator

Ludmila Abrahão Hajjar

UNKNOWN

collaborator

Jorge Souza Mendonça

UNKNOWN

lead

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

OTHER

NCT04323527 - Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2 | Biotech Hunter | Biotech Hunter